On September 17, 2020 Halozyme Therapeutics, Inc. (NASDAQ: HALO) reported that its collaborator, Roche, presented a poster with data from Part 1 of its Phase 1b study (IMscin001) evaluating atezolizumab (Tecentriq) for subcutaneous administration utilizing Halozyme’s ENHANZE technology in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) at the ESMO (Free ESMO Whitepaper) Virtual Congress 2020 (Press release, Halozyme, SEP 17, 2020, View Source [SID1234565283]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Phase 1b dose-finding study enrolled 67 patients with advanced/metastatic NSCLC previously treated with chemotherapy (no prior cancer immunotherapy) in 3 cohorts. The poster concluded that atezolizumab utilizing ENHANZE was well tolerated, provided similar exposure as atezolizumab IV and that results support further development of subcutaneous atezolizumab in IMscin001 Part 2, a confirmatory phase III study.

"We are pleased that the results from Roche’s Phase 1b evaluating atezolizumab with ENHANZE support continued development in a Phase 3 study," said Dr. Helen Torley, president and chief executive officer.

The subcutaneous formulation of atezolizumab is being developed to potentially allow faster administration via subcutaneous injection under the skin, compared to the original intravenous (IV) formulation, thereby significantly reducing a patient’s time spent receiving treatment.